Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Piramal Pharma Solutions Canada Germany United Kingdom France Switzerland United States of America Italy India Spain Austria

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand.Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development.| LinkedIn

* Includes one facility via PPL's minority investment in Yapan Bio.

Photo : https://mma.prnewswire.com/media/2755167/Peter_DeYoung.jpg
Photo : https://mma.prnewswire.com/media/2755168/Douglas_Kling.jpg
Photo : https://mma.prnewswire.com/media/2755169/Group_Photo.jpg
Logo : https://mma.prnewswire.com/media/2755170/NewAmsterdam_Logo.jpg
Logo : https://mma.prnewswire.com/media/1726186/4941829/Piramal_Pharma_Solutions_Logo.jpg

 

 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-solutions-and-newamsterdam-pharma-invest-in-dedicated-suite-to-enhance-oral-solid-dosage-production-capabilities-at-piramals-sellersville-pennsylvania-site-302535572.html